Clavis Pharma ASA has decided to expand the scope of its Phase 3 trial of the compound, elacytarabine for acute myeloid leukaemia, to include patients over the age of 65 with a poor prognosis. Top-line data are expected in the 2012 fourth quarter. ---Subscribe to MedNous to access this article--- Company News
